The "Prescription Drug Supply Chain Pricing Transparency Act" or H.R. 7535, is a bill that directs the Comptroller General of the United States to conduct a comprehensive study on compensation and payment structures within the prescription drug supply chain that are related to a drug's price. Key provisions of the bill include:
Action Date | Type | Text | Source |
---|---|---|---|
2024-12-17 | Committee | Referred to the Subcommittee on Health. | House committee actions |
2024-03-08 | Committee | Referred to the Subcommittee on Health. | House committee actions |
2024-03-05 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
2024-03-05 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
2024-03-05 | IntroReferral | Introduced in House | Library of Congress |